Petros Pharmaceuticals, Inc. (PTPI)

Petros Pharmaceuticals, Inc. (PTPI) Healthcare & Pipeline Overview

Petros Pharmaceuticals, Inc. is a pharmaceutical company specializing in men's health, particularly erectile dysfunction (ED) and Peyronie's disease. Their key product, Stendra, targets ED, while H100 is under development for Peyronie's. The company operates within the specialty and generic drug manufacturing sector, focusing on unmet needs in men's health.

What Is the Investment Thesis for PTPI?

Petros Pharmaceuticals presents a focused approach to men's health, primarily through Stendra for erectile dysfunction and the investigational drug H100 for Peyronie's disease. With a gross margin of 63.5%, the company demonstrates potential for profitability, although the current profit margin is -968.2%. Key to the investment thesis is the successful commercialization of H100, which could address a significant unmet need. The company's high beta of 1.66 suggests higher volatility compared to the market. Upcoming catalysts include clinical trial updates for H100 and potential partnerships to expand market reach. Investors should monitor the company's ability to manage its expenses and achieve profitability.

Based on FMP financials and quantitative analysis

PTPI Key Highlights

• Gross Margin of 63.5% indicates strong potential for profitability on sales.
• Focus on men's health therapeutics provides a niche market opportunity.
• Development of H100 for Peyronie's disease addresses an unmet medical need.
• Stendra, a PDE-5 inhibitor, is the company's key commercialized product for erectile dysfunction.
• Market Capitalization of 125K reflects the company's current small size and potential for growth.

Who Are PTPI's Competitors?

PTPI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PTPI's Key Strengths?

• Focus on men's health therapeutics.
• Commercialized product (Stendra) generating revenue.
• Development of H100 addressing an unmet need.
• Established distribution network for Stendra.

What Are PTPI's Weaknesses?

• Limited product portfolio.
• High operating expenses.
• Dependence on Stendra for revenue.
• Negative profit margin.

What Could Drive PTPI Stock Higher?

• Clinical trial results for H100 for Peyronie's disease.
• Potential partnerships to expand market reach for Stendra.
• Efforts to increase sales and market share of Stendra.
• Research and development activities for new formulations and delivery systems.

What Are the Key Risks for PTPI?

• Financial-distress signal — its Altman Z-Score of -38.47 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established pharmaceutical companies with greater resources.
• Regulatory setbacks in the approval process for H100.
• Dependence on Stendra for a significant portion of revenue.
• Fluctuations in market demand for erectile dysfunction treatments.

What Are the Growth Opportunities for PTPI?

• Expansion of Stendra Market Reach: Petros Pharmaceuticals can expand the market reach of Stendra through strategic partnerships, targeted marketing campaigns, and geographic expansion. The global erectile dysfunction market is projected to reach billions of dollars, offering significant growth potential for Stendra. Timeline: Ongoing, with continuous efforts to increase market penetration.
• Successful Development and Commercialization of H100: The successful development and commercialization of H100 for Peyronie's disease represents a significant growth opportunity. Peyronie's disease affects a considerable percentage of men, and H100 could become a leading treatment option if approved. Timeline: Dependent on clinical trial results and regulatory approvals, estimated within the next 2-3 years.
• Strategic Acquisitions and Partnerships: Petros Pharmaceuticals can pursue strategic acquisitions and partnerships to expand its product portfolio and market presence. Acquiring or partnering with companies that have complementary products or technologies in men's health could accelerate growth. Timeline: Opportunistic, based on available opportunities and strategic fit.
• Development of New Formulations and Delivery Systems: Petros Pharmaceuticals can invest in the development of new formulations and delivery systems for its existing products and pipeline candidates. This could improve patient compliance, enhance efficacy, and extend patent protection. Timeline: Ongoing, with continuous research and development efforts.
• Geographic Expansion into International Markets: Petros Pharmaceuticals can expand its geographic presence into international markets, particularly in regions with growing economies and increasing healthcare spending. This would diversify its revenue streams and reduce reliance on the US market. Timeline: Long-term, with careful consideration of regulatory requirements and market dynamics.

What Opportunities Does PTPI Have?

• Expansion of Stendra market reach.
• Successful commercialization of H100.
• Strategic partnerships and acquisitions.
• Development of new formulations and delivery systems.

What Threats Does PTPI Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles for new drug approvals.
• Patent expiration for key products.
• Economic downturn affecting healthcare spending.

What Are PTPI's Competitive Advantages?

• Patent protection for H100 provides a competitive advantage in the Peyronie's disease market.
• Established brand recognition for Stendra in the erectile dysfunction market.
• Focus on a specific niche within the pharmaceutical industry (men's health).
• Proprietary formulations and delivery systems for its products.

What Does PTPI Do?

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to addressing unmet medical needs in men's health. The company's primary focus is on the commercialization and development of therapeutics for conditions such as erectile dysfunction (ED) and Peyronie's disease. Petros Pharmaceuticals' lead product is Stendra, a PDE-5 inhibitor prescription medication used for the treatment of ED. Stendra is a key revenue driver for the company, offering a treatment option for men experiencing erectile dysfunction. In addition to Stendra, Petros Pharmaceuticals is developing H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. Peyronie's disease is a condition characterized by the development of fibrous plaques in the penis, leading to pain and curvature during erection. H100 represents a potential novel treatment option for this condition. The company also markets vacuum erection device products, expanding its portfolio of solutions for ED. Petros Pharmaceuticals, Inc. is based in New York, New York, and manages its operations with a team of 18 employees.

What Products and Services Does PTPI Offer?

• Develop and commercialize Stendra, a prescription medication for erectile dysfunction (ED).
• Develop H100, a topical formulation candidate for the treatment of acute Peyronie's disease.
• Market vacuum erection device products for ED.
• Focus on addressing unmet medical needs in men's health.
• Conduct clinical trials to evaluate the safety and efficacy of H100.
• Seek regulatory approvals for new products and indications.

How Does PTPI Make Money?

• Develop, market, and sell pharmaceutical products focused on men's health.
• Generate revenue through sales of Stendra and vacuum erection devices.
• Invest in research and development to expand product pipeline.
• Seek partnerships and collaborations to expand market reach and product offerings.

What Industry Does PTPI Operate In?

Petros Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The market for men's health therapeutics is driven by factors such as aging populations, changing lifestyles, and increased awareness of medical conditions. The competitive landscape includes companies focusing on similar therapeutic areas, as well as larger pharmaceutical companies with broader product portfolios. Petros Pharmaceuticals' focus on specific men's health conditions like ED and Peyronie's disease allows it to potentially capture a niche market share.

Who Are PTPI's Key Customers?

• Men experiencing erectile dysfunction (ED).
• Men diagnosed with Peyronie's disease.
• Healthcare providers who prescribe and recommend Petros Pharmaceuticals' products.
• Pharmacies and distributors that stock and sell Petros Pharmaceuticals' products.

Net buyingInsider Activity

Over the past six months, Petros Pharmaceuticals, Inc. insiders filed 4 SEC Form 4 transactions — 0 sales and 4 purchases. On net that is roughly 7.0M shares acquired (about $0) — insiders putting money in tends to read as conviction.

PTPI Valuation & Market Position

With a 125K market cap, Petros Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PTPI's quantitative score of 33/100 is below the peer average of 65/100.

ROE 102%Key Financial Metrics

Return on equity for Petros Pharmaceuticals, Inc. stands at 102.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 72.5%, showing how much profit it generates from its asset base. PTPI trades at a trailing price-to-earnings ratio of 0.09, below the Healthcare sector average of ~23x. A current ratio of 1.68 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 3/9Financial Health

Petros Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -38.47 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Petros Pharmaceuticals, Inc. revenue of about $11.0M for fiscal 2026, with EPS near $-27.50.

Company Profile

Petros Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Joshua N. Silverman. PTPI has traded publicly since 2020.

PTPI Financials

PTPI Latest News

No recent news available for PTPI.

PTPI Analyst Consensus

PTPI MoonshotScore

Petros Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources